Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Häufige urologisch-sexualmedizinische Themen in der Praxis sind das Thema des MMW-Webinars am 5. Juni von 17.30 bis 19 Uhr. Konkret geht es um die Frage, wann bei Harnwegsinfektionen auf Antibiotika verzichtet werden kann, und um ein Update zur Therapie von Libido- und Potenzstörungen des Mannes. Der dritte Vortrag behandelt sexuell übertragbare Krankheiten. Stellen Sie Ihre Fragen an die Experten und sammeln Sie 2 CME-Punkte. Jetzt gleich anmelden!
Erweiterte Suche
Anmelden
nach oben
Molecular Diagnosis & Therapy
Erschienen in: Molecular Diagnosis & Therapy 4/2018

01.08.2018 | Review Article

The Role of DNA Methylation in Renal Cell Carcinoma

verfasst von: Brittany N. Lasseigne, James D. Brooks

Erschienen in: Molecular Diagnosis & Therapy | Ausgabe 4/2018

Einloggen, um Zugang zu erhalten

Abstract

Renal cell carcinoma (RCC) is the most common kidney cancer and includes several molecular and histological subtypes with different clinical characteristics. While survival rates are high if RCC is diagnosed when still confined to the kidney and treated definitively, there are no specific diagnostic screening tests available and symptoms are rare in early stages of the disease. Management of advanced RCC has changed significantly with the advent of targeted therapies, yet survival is usually increased by months due to acquired resistance to these therapies. DNA methylation, the covalent addition of a methyl group to a cytosine, is essential for normal development and transcriptional regulation, but becomes altered commonly in cancer. These alterations result in broad transcriptional changes, including in tumor suppressor genes. Because DNA methylation is one of the earliest molecular changes in cancer and is both widespread and stable, its role in cancer biology, including RCC, has been extensively studied. In this review, we examine the role of DNA methylation in RCC disease etiology and progression, the preclinical use of DNA methylation alterations as diagnostic, prognostic and predictive biomarkers, and the potential for DNA methylation-directed therapies.
Literatur
1.
2.
Chen F, Zhang Y, Şenbabaoğlu Y, Ciriello G, Yang L, Reznik E, et al. Multilevel genomics-based taxonomy of renal cell carcinoma. Cell Rep. 2016;14:2476–89.PubMedPubMedCentralCrossRef
3.
Hsieh JJ, Le V, Cao D, Cheng EH, Creighton CJ. Genomic classifications of renal cell carcinoma: a critical step towards the future application of personalized kidney cancer care with panomics precision. J Pathol. 2018;244:525–37.PubMedCrossRef
4.
Lightfoot N, Conlon M, Kreiger N, Bissett R, Desai M, Warde P, et al. Impact of noninvasive imaging on increased incidental detection of renal cell carcinoma. Eur Urol. 2000;37:521–7.PubMedCrossRef
5.
Silverman SG, Israel GM, Herts BR, Richie JP. Management of the incidental renal mass. Radiology. 2008;249:16–31.PubMedCrossRef
6.
Howlader N, Noone A, Krapcho M, Garshell J, Miller D, Altekruse S, et al. SEER cancer statistics review, 1975–2012. Rockville: National Cancer Institute; 2015.
7.
Hsieh JJ, Purdue MP, Signoretti S, Swanton C, Albiges L, Schmidinger M, et al. Renal cell carcinoma. Nat Rev Dis Prim. 2017;3:17009.PubMedCrossRef
8.
Jonasch E, Futreal PA, Davis IJ, Bailey ST, Kim WY, Brugarolas J, et al. State of the science: an update on renal cell carcinoma. Mol Cancer Res. 2012;10:859–80.PubMedPubMedCentralCrossRef
9.
10.
11.
Gnarra JR, Tory K, Weng Y, Schmidt L, Wei MH, Li H, et al. Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat Genet. 1994;7:85–90.PubMedCrossRef
12.
Creighton CJ, Morgan M, Gunaratne PH, Wheeler DA, Gibbs RA, Gordon Robertson A, et al. Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature. 2013;499:43–9.CrossRef
13.
Rankin EB, Tomaszewski JE, Haase VH. Renal cyst development in mice with conditional inactivation of the von Hippel–Lindau tumor suppressor. Cancer Res. 2006;66:2576–83.PubMedPubMedCentralCrossRef
14.
15.
Cancer Genome Atlas Research Network. Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature. 2013;499:43–9.CrossRef
16.
Varela I, Tarpey P, Raine K, Huang D, Ong CK, Stephens P, et al. Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma. Nature. 2011;469:539–42.PubMedPubMedCentralCrossRef
17.
Ricketts CJ, De Cubas AA, Fan H, Smith CC, Lang M, Reznik E, et al. The cancer genome atlas comprehensive molecular characterization of renal cell carcinoma. Cell Rep. 2018;23:313–26.PubMedCrossRef
18.
Nargund AM, Pham CG, Dong Y, Wang PI, Osmangeyoglu HU, Xie Y, et al. The SWI/SNF protein PBRM1 restrains VHL-loss-driven clear cell renal cell carcinoma. Cell Rep. 2017;18:2893–906.PubMedPubMedCentralCrossRef
19.
Montero LM, Filipski J, Gil P, Capel J, Martinez-Zapater JM, Salinas J. The distribution of 5-methylcytosine in the nuclear genome of plants. Nucleic Acids Res. 1992;20:3207–10.PubMedPubMedCentralCrossRef
20.
21.
Ushijima T. Detection and interpretation of altered methylation patterns in cancer cells. Nat Rev Cancer. 2005;5:223–31.PubMedCrossRef
22.
23.
24.
Wu P, Cao Z, Wu S. New progress of epigenetic biomarkers in urological cancer. Dis Markers. 2016;2016:1–8.
25.
26.
Kanai Y. Genome-wide DNA methylation profiles in precancerous conditions and cancers. Cancer Sci. 2010;101:36–45.PubMedCrossRef
27.
Arai E, Kanai Y. Genetic and epigenetic alterations during renal carcino-genesis. Int J Clin Pathol. 2011;4:58–73.
28.
NCBI Resource Coordinators. Database resources of the national center for biotechnology information. Nucleic Acids Res. 2017;45:D12–7.CrossRef
29.
Herman JG, Latif F, Weng Y, Lerman MI, Zbar B, Liu S, et al. Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. Proc Natl Acad Sci USA. 1994;91:9700–4.PubMedCrossRef
30.
Clifford SC, Prowse AH, Affara NA, Buys CH, Maher ER. Inactivation of the von Hippel-Lindau (VHL) tumour suppressor gene and allelic losses at chromosome arm 3p in primary renal cell carcinoma: evidence for a VHL-independent pathway in clear cell renal tumourigenesis. Genes Chromosomes Cancer. 1998;22:200–9.PubMedCrossRef
31.
Yang L, Zhao Z, Zhao S, Chen C, Cong X, Li Z, et al. The clinicopathological significance of epigenetic silencing of VHL promoter and renal cell carcinoma: a meta-analysis. Cell Physiol Biochem. 2016;40:1465–72.PubMedCrossRef
32.
33.
Morrissey C, Martinez A, Zatyka M, Agathanggelou A, Honorio S, Astuti D, et al. Epigenetic inactivation of the RASSF1A 3p21.3 tumor suppressor gene in both clear cell and papillary renal cell carcinoma. Cancer Res. 2001;61:7277–81.PubMed
34.
35.
Yu G-S, Lai C-Y, Xu Y, Bu C-F, Su Z-X. Aberrant methylation of RASSF1A gene contribute to the risk of renal cell carcinoma: a meta-analysis. Asian Pac J Cancer Prev. 2015;16:4665–9.PubMedCrossRef
36.
Wang J, Ren Y, Guo X, Cheng H, Ye Y, Qi J, et al. Alterations in enhancer of zeste homolog 2, matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 expression are associated with ex vivo and in vitro bone metastasis in renal cell carcinoma. Mol Med Rep. 2015;11:3585–92.PubMedCrossRef
37.
Shenoy N, Vallumsetla N, Zou Y, Galeas JN, Shrivastava M, Hu C, et al. Role of DNA methylation in renal cell carcinoma. J Hematol Oncol. 2015;8:88.PubMedPubMedCentralCrossRef
38.
Morris MR, Ricketts CJ, Gentle D, McRonald F, Carli N, Khalili H, et al. Genome-wide methylation analysis identifies epigenetically inactivated candidate tumour suppressor genes in renal cell carcinoma. Oncog Nat Publ Group. 2011;30:1390–401.
39.
McRonald FE, Morris MR, Gentle D, Winchester L, Baban D, Ragoussis J, et al. CpG methylation profiling in VHL related and VHL unrelated renal cell carcinoma. Mol Cancer. 2009;8:31.PubMedPubMedCentralCrossRef
40.
Arai E, Ushijima S, Tsuda H. Genetic clustering of clear cell renal cell carcinoma based on array-comparative genomic hybridization: its association with DNA methylation alteration and patient outcome. Clin Cancer Res. 2008;14:5531–9.PubMedCrossRef
41.
Arai E, Chiku S, Mori T, Gotoh M, Nakagawa T, Fujimoto H, et al. Single-CpG-resolution methylome analysis identifies clinicopathologically aggressive CpG island methylator phenotype clear cell renal cell carcinomas. Carcinogenesis. 2012;33:1487–93.PubMedPubMedCentralCrossRef
42.
Mendoza-Perez J, Gu J, Herrera LA, Tannir NM, Matin SF, Karam JA, et al. Genomic DNA hypomethylation and risk of renal cell carcinoma: a case–control study. Clin Cancer Res. 2016;22:2074–82.PubMedCrossRef
43.
Ramakrishnan N, Bose R. Analysis of distribution of DNA methylation in kidney-renal-clear-cell-carcinoma specific genes using entropy. Genom Data. 2016;10:109–13.PubMedPubMedCentralCrossRef
44.
Hu CY, Mohtat D, Yu Y, Ko Y-A, Shenoy N, Bhattacharya S, et al. Kidney cancer is characterized by aberrant methylation of tissue-specific enhancers that are prognostic for overall survival. Clin Cancer Res. 2014;20:4349–60.PubMedPubMedCentralCrossRef
45.
Liu Y, Sun L, Fong P, Yang J, Zhang Z, Yin S, et al. An association between overexpression of DNA methyltransferase 3B4 and clear cell renal cell carcinoma. Oncotarget Impact J. 2017;8:19712–22.
46.
Mahalingaiah PKS, Ponnusamy L, Singh KP. Oxidative stress-induced epigenetic changes associated with malignant transformation of human kidney epithelial cells. Oncotarget. 2016;8:11127–43.PubMedCentral
47.
48.
Tiedemann RL, Hlady RA, Hanavan PD, Lake DF, Tibes R, Lee J-H, et al. Dynamic reprogramming of DNA methylation in SETD2-deregulated renal cell carcinoma. Oncotarget. 2016;7:1927–46.PubMedCrossRef
49.
Liu L, Guo R, Zhang X, Liang Y, Kong F, Wang J, et al. Loss of SETD2, but not H3K36me3, correlates with aggressive clinicopathological features of clear cell renal cell carcinoma patients. Biosci Trends. 2017;11:214–20.PubMedCrossRef
50.
Wang Y, Guo X, Bray MJ, Ding Z, Zhao Z. An integrative genomics approach for identifying novel functional consequences of PBRM1 truncated mutations in clear cell renal cell carcinoma (ccRCC). BMC Genom. 2016;17:515.CrossRef
51.
He C, Zhao X, Jiang H, Zhong Z, Xu R. Demethylation of miR-10b plays a suppressive role in ccRCC cells. Int J Clin Exp Pathol. 2015;8:10595–604.PubMedPubMedCentral
52.
Hildebrandt MAT, Gu J, Lin J, Ye Y, Tan W, Tamboli P, et al. Hsa-miR-9 methylation status is associated with cancer development and metastatic recurrence in patients with clear cell renal cell carcinoma. Oncogene. 2010;29:5724–8.PubMedCrossRef
53.
Johnson DC, Vukina J, Smith AB, Meyer A-M, Wheeler SB, Kuo T-M, et al. Preoperatively misclassified, surgically removed benign renal masses: a systematic review of surgical series and United States population level burden estimate. J Urol. 2015;193:30–5.PubMedCrossRef
54.
Haas NB, Nathanson KL. Hereditary kidney cancer syndromes. Adv Chronic Kidney Dis. 2014;21:81–90.PubMedCrossRef
55.
Mikeska T, Bock C, Do H, Dobrovic A. DNA methylation biomarkers in cancer: progress towards clinical implementation. Expert Rev Mol Diagn. 2012;12:473–87.PubMedCrossRef
56.
Battagli C, Uzzo RG, Dulaimi E, Ibanez de Caceres I, Krassenstein R, Al-Saleem T, et al. Promoter hypermethylation of tumor suppressor genes in urine from kidney cancer patients. Cancer Res. 2003;63:8695–9.PubMed
57.
Hoque MO, Begum S, Topaloglu O, Jeronimo C, Mambo E, Westra WH, et al. Quantitative detection of promoter hypermethylation of multiple genes in the tumor, urine, and serum DNA of patients with renal cancer. Cancer Res. 2004;64:5511–7.PubMedCrossRef
58.
Hauser S, Zahalka T, Fechner G, Müller SC, Ellinger J. Serum DNA hypermethylation in patients with kidney cancer: results of a prospective study. Anticancer Res. 2013;33:4651–6.PubMed
59.
60.
Skrypkina I, Tsyba L, Onyshchenko K, Morderer D, Kashparova O, Nikolaienko O, et al. Concentration and methylation of cell-free DNA from blood plasma as diagnostic markers of renal cancer. Dis Markers. 2016;2016:1–10.CrossRef
61.
Lasseigne BN, Burwell TC, Patil MA, Absher DM, Brooks JD, Myers RM. DNA methylation profiling reveals novel diagnostic biomarkers in renal cell carcinoma. BMC Med. 2014;12:235.PubMedPubMedCentralCrossRef
62.
Chopra S, Liu J, Alemozaffar M, Nichols PW, Aron M, Weisenberger DJ, et al. Improving needle biopsy accuracy in small renal mass using tumor-specific DNA methylation markers. Oncotarget. 2017;8:5439–48.PubMedCrossRef
63.
Slater AA, Alokail M, Gentle D, Yao M, Kovacs G, Maher ER, et al. DNA methylation profiling distinguishes histological subtypes of renal cell carcinoma. Epigenetics. 2013;8:252–67.PubMedPubMedCentralCrossRef
64.
Malouf GG, Su X, Zhang J, Creighton CJ, Ho TH, Lu Y, et al. DNA methylation signature reveals cell ontogeny of renal cell carcinomas. Clin Cancer Res. 2016;22:6236–46.PubMedPubMedCentralCrossRef
65.
Ristau BT, Kutikov A, Uzzo RG, Smaldone MC. Active surveillance for small renal masses: when less is more. Eur Urol Focus. 2016;2:660–8.PubMedCrossRef
66.
Ravaud A, Motzer RJ, Pandha HS, George DJ, Pantuck AJ, Patel A, et al. Adjuvant sunitinib in high-risk renal-cell carcinoma after nephrectomy. N Engl J Med. 2016;375:2246–54.PubMedCrossRef
67.
Golovastova MO, Korolev DO, Tsoy LV, Varshavsky VA, Xu W-H, Vinarov AZ, et al. Biomarkers of renal tumors: the current state and clinical perspectives. Curr Urol Rep. 2017;18:3.PubMedCrossRef
68.
69.
Tezval H, Dubrowinskaja N, Peters I, Reese C, Serth K, Atschekzei F, et al. Tumor specific epigenetic silencing of corticotropin releasing hormone-binding protein in renal cell carcinoma: association of hypermethylation and metastasis. Castresana JS, editor. PLoS One. 2016;11:e0163873.PubMedPubMedCentralCrossRef
70.
Zhao H, Leppert JT, Peehl DM. A protective role for androgen receptor in clear cell renal cell carcinoma based on mining TCGA data. Chai KX, editor. PLoS One. 2016;11:e0146505.PubMedPubMedCentralCrossRef
71.
Mitsui Y, Hirata H, Arichi N, Hiraki M, Yasumoto H, Chang I, et al. Inactivation of bone morphogenetic protein 2 may predict clinical outcome and poor overall survival for renal cell carcinoma through epigenetic pathways. Oncotarget. 2015;6:9577–91.PubMedPubMedCentralCrossRef
72.
Deckers IAG, Schouten LJ, Van Neste L, van Vlodrop IJH, Soetekouw PMMB, Baldewijns MMLL, et al. Promoter methylation of CDO1 identifies clear-cell renal cell cancer patients with poor survival outcome. Clin Cancer Res. 2015;21:3492–500.PubMedPubMedCentralCrossRef
73.
Wang Z-R, Wei J-H, Zhou J-C, Haddad A, Zhao L-Y, Kapur P, et al. Validation of DAB2IP methylation and its relative significance in predicting outcome in renal cell carcinoma. Oncotarget Impact J. 2016;7:31508–19.
74.
Pio Fabrizio F, Costantini M, Copetti M, la Torre A, Sparaneo A, Fontana A, et al. Keap1/Nrf2 pathway in kidney cancer: frequent methylation of KEAP1 gene promoter in clear renal cell carcinoma. Oncotarget. 2017;8:11187–98.
75.
76.
van Vlodrop IJH, Joosten SC, De Meyer T, Smits KM, Van Neste L, Melotte V, et al. A four-gene promoter methylation marker panel consisting of GREM1, NEURL, LAD1, and NEFH predicts survival of clear cell renal cell cancer patients. Clin Cancer Res. 2017;23:2006–18.PubMedCrossRef
77.
Evelönn EA, Degerman S, Köhn L, Landfors M, Ljungberg B, Roos G. DNA methylation status defines clinicopathological parameters including survival for patients with clear cell renal cell carcinoma (ccRCC). Tumor Biol. 2016;37:10219–28.CrossRef
78.
Tian Y, Arai E, Gotoh M, Komiyama M, Fujimoto H, Kanai Y. Prognostication of patients with clear cell renal cell carcinomas based on quantification of DNA methylation levels of CpG island methylator phenotype marker genes. BMC Cancer. 2014;14:772.PubMedPubMedCentralCrossRef
79.
Arai E, Gotoh M, Tian Y, Sakamoto H, Ono M, Matsuda A, et al. Alterations of the spindle checkpoint pathway in clinicopathologically aggressive CpG island methylator phenotype clear cell renal cell carcinomas. Int J cancer. 2015;137:2589–606.PubMedPubMedCentralCrossRef
80.
Cancer Genome Atlas Research Network, Linehan WM, Spellman PT, Ricketts CJ, Creighton CJ, Fei SS, et al. Comprehensive molecular characterization of papillary renal-cell carcinoma. N Engl J Med. 2016;374:135–45.CrossRef
81.
Xiao M, Yang H, Xu W, Ma S, Lin H, Zhu H, et al. Inhibition of -KG-dependent histone and DNA demethylases by fumarate and succinate that are accumulated in mutations of FH and SDH tumor suppressors. Genes Dev. 2012;26:1326–38.PubMedPubMedCentralCrossRef
82.
Chen K, Zhang J, Guo Z, Ma Q, Xu Z, Zhou Y, et al. Loss of 5-hydroxymethylcytosine is linked to gene body hypermethylation in kidney cancer. Cell Res. 2016;26:103–18.PubMedCrossRef
83.
Chen G, Wang Y, Wang L, Xu W. Identifying prognostic biomarkers based on aberrant DNA methylation in kidney renal clear cell carcinoma. Oncotarget. 2017;8:5268–80.PubMed
84.
Dimitrieva S, Schlapbach R, Rehrauer H. Prognostic value of cross-omics screening for kidney clear cell renal cancer survival. Biol Direct. 2016;11:68.PubMedPubMedCentralCrossRef
85.
Wei J-H, Haddad A, Wu K-J, Zhao H-W, Kapur P, Zhang Z-L, et al. A CpG-methylation-based assay to predict survival in clear cell renal cell carcinoma. Nat Commun. 2015;6:8699.PubMedPubMedCentralCrossRef
86.
Joosten SC, Deckers IA, Aarts MJ, Hoeben A, van Roermund JG, Smits KM, et al. Prognostic DNA methylation markers for renal cell carcinoma: a systematic review. Epigenomics. 2017;9(9):1243–57.PubMedCrossRef
87.
88.
Stewart GD, Powles T, Van Neste C, Meynert A, O’Mahony F, Laird A, et al. Dynamic epigenetic changes to VHL occur with sunitinib in metastatic clear cell renal cancer. Oncotarget Impact J. 2016;7:25241–50.
89.
90.
91.
92.
93.
94.
Han T, Shang D, Xu X, Tian Y. Gene expression profiling of the synergy of 5-aza-2′-deoxycytidine and paclitaxel against renal cell carcinoma. World J Surg Oncol. 2012;10:183.PubMedPubMedCentralCrossRef
95.
Shang D, Liu Y, Xu X, Han T, Tian Y. 5-Aza-2′-deoxycytidine enhances susceptibility of renal cell carcinoma to paclitaxel by decreasing LEF1/phospho-β-catenin expression. Cancer Lett. 2011;311:230–6.PubMedCrossRef
96.
97.
Gollob JA, Sciambi CJ, Peterson BL, Richmond T, Thoreson M, Moran K, et al. Phase I trial of sequential low-dose 5-aza-2′-deoxycytidine plus high-dose intravenous bolus interleukin-2 in patients with melanoma or renal cell carcinoma. Clin Cancer Res Am Assoc Cancer Res. 2006;12:4619–27.CrossRef
98.
Abele R, Clavel M, Dodion P, Bruntsch U, Gundersen S, Smyth J, et al. The EORTC Early Clinical Trials Cooperative Group experience with 5-aza-2′-deoxycytidine (NSC 127716) in patients with colorectal, head and neck, renal carcinomas and malignant melanomas. Eur J Cancer Clin Oncol. 1987;23:1921–4.PubMedCrossRef
99.
Shang D, Han T, Xu X, Liu Y. Decitabine induces G2/M cell cycle arrest by suppressing p38/NF-κB signaling in human renal clear cell carcinoma. Int J Clin Exp Pathol. 2015;8:11140–8.PubMedPubMedCentral
100.
Saleh MH, Wang L, Goldberg MS. Improving cancer immunotherapy with DNA methyltransferase inhibitors. Cancer Immunol Immunother. 2016;65:787–96.PubMedCrossRef
101.
Coral S, Sigalotti L, Altomonte M, Engelsberg A, Colizzi F, Cattarossi I, et al. 5-aza-2′-deoxycytidine-induced expression of functional cancer testis antigens in human renal cell carcinoma: immunotherapeutic implications. Clin Cancer Res. 2002;8:2690–5.PubMed
102.
103.
Bhagat TD, Zou Y, Huang S, Park J, Palmer MB, Hu C, et al. Notch pathway is activated via genetic and epigenetic alterations and is a therapeutic target in clear cell renal cancer. J Biol Chem. 2017;292:837–46.PubMedCrossRef
104.
Hamilton E, Infante JR. Targeting CDK4/6 in patients with cancer. Cancer Treat Rev. 2016;45:129–38.PubMedCrossRef
105.
Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015;373:1803–13.PubMedPubMedCentralCrossRef
106.
Miao D, Margolis CA, Gao W, Voss MH, Li W, Martini DJ, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Sci Am Assoc Adv Sci. 2018;359:801–6.
107.
Bradley AJ, Lim YY, Singh FM. Imaging features, follow-up, and management of incidentally detected renal lesions. Clin Radiol. 2011;66:1129–39.PubMedCrossRef
108.
Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med. 2012;366:883–92.PubMedPubMedCentralCrossRef
109.
Faleiro I, Leão R, Binnie A, de Mello RA, Maia A-T, Castelo-Branco P. Epigenetic therapy in urologic cancers: an update on clinical trials. Oncotarget Impact J. 2017;8:12484–500.
110.
Day K, Waite LL, Thalacker-Mercer A, West A, Bamman MM, Brooks JD, et al. Differential DNA methylation with age displays both common and dynamic features across human tissues that are influenced by CpG landscape. Genome Biol. 2013;14:R102.PubMedPubMedCentralCrossRef
111.
Rius M, Lyko F. Epigenetic cancer therapy: rationales, targets and drugs. Oncog Nat Publ Group. 2012;31:4257–65.
112.
113.
Metadaten
Titel
The Role of DNA Methylation in Renal Cell Carcinoma
verfasst von
Brittany N. Lasseigne
James D. Brooks
Publikationsdatum
01.08.2018
Verlag
Springer International Publishing
Erschienen in
Molecular Diagnosis & Therapy / Ausgabe 4/2018
Print ISSN: 1177-1062
Elektronische ISSN: 1179-2000
DOI
https://doi.org/10.1007/s40291-018-0337-9

Weitere Artikel der Ausgabe 4/2018

Molecular Diagnosis & Therapy 4/2018 Zur Ausgabe

Original Research Article

Molecular and Immnune Diagnosis: Further Testing for Human Strongyloidiasis

Short Communication

The Presence of HLA-A Bw4-80I KIR Ligands Could Predict “Difficult-to-Treat” Psoriasis and Poor Response to Etanercept

Review Article

Molecular Diagnosis of Visceral Leishmaniasis

Systematic Review

Association Between CHEK2*1100delC and Breast Cancer: A Systematic Review and Meta-Analysis

Short Communication

Whipple’s Disease: Diagnostic Value of rpoB Gene PCR from Peripheral Blood Mononuclear Cells

Letter to the Editor

Comment on “Targeting AMPK, mTOR and β-Catenin by Combined Metformin and Aspirin Therapy in HCC: An Appraisal in Egyptian HCC Patients”

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Perioperative Checkpointhemmer-Therapie verbessert NSCLC-Prognose

28.05.2024 NSCLC Nachrichten

Eine perioperative Therapie mit Nivolumab reduziert das Risiko für Rezidive und Todesfälle bei operablem NSCLC im Vergleich zu einer alleinigen neoadjuvanten Chemotherapie um über 40%. Darauf deuten die Resultate der Phase-3-Studie CheckMate 77T.

Positiver FIT: Die Ursache liegt nicht immer im Dickdarm

27.05.2024 Blut im Stuhl Nachrichten

Immunchemischer Stuhltest positiv, Koloskopie negativ – in solchen Fällen kann die Blutungsquelle auch weiter proximal sitzen. Ein Forschungsteam hat nachgesehen, wie häufig und in welchen Lokalisationen das der Fall ist.

GLP-1-Agonisten können Fortschreiten diabetischer Retinopathie begünstigen

24.05.2024 Diabetische Retinopathie Nachrichten

Möglicherweise hängt es von der Art der Diabetesmedikamente ab, wie hoch das Risiko der Betroffenen ist, dass sich sehkraftgefährdende Komplikationen verschlimmern.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise